You're Taking Omega-3s, but Your Genes May Be Blocking Them.

FADS1 encodes delta-5 desaturase, an enzyme that sits at a critical step in the conversion of short-chain omega-3s (like ALA from flaxseed) into long-chain omega-3s (EPA and DHA, the forms your brain and heart actually use). Think of it as a molecular scissors that cuts and rearranges fatty acid molecules. Without it working properly, the conversion never happens.

The rs174537 variant in FADS1, carried by roughly 30-40% of people with European ancestry, reduces delta-5 desaturase activity. People with this variant convert ALA to EPA at roughly half the rate of people without it. Your dietary flaxseed, chia seeds, and walnuts sit in your body unable to be transformed into the forms your tissues need.

You might notice you feel less mentally sharp when you rely on plant-based omega-3s alone. Your mood might dip. Your joint flexibility might suffer. Your blood markers might show lower EPA and DHA despite eating all the right foods. Standard nutritionists see this and say eat more omega-3 sources. But your enzyme is already working as hard as it can.

FADS2 encodes delta-6 desaturase, the enzyme that catalyzes the very first critical step in converting ALA into the omega-3 pathway. It sits upstream of FADS1. If FADS2 is impaired, the conversion chain never even starts properly. This is the gatekeeper enzyme.

The rs1535 variant in FADS2, present in roughly 30-40% of the population, reduces delta-6 desaturase activity. People with this variant have impaired activation of the entire omega-3 conversion pathway. Even if your FADS1 is perfectly normal, if FADS2 is compromised, the substrate for FADS1 never arrives in sufficient quantity.

You might feel like omega-3 supplements don’t work for you at all. You might have inflammatory markers that don’t improve despite dietary changes. You might have tried fish oil at various doses and felt no cognitive or mood benefit. Your doctor might say your omega-3 levels are fine, but you intuitively feel like something is off. That intuition is your cells responding to functional omega-3 insufficiency at the cellular level.

PPARG is not directly a fatty acid metabolism gene, but it controls how your cells respond to omega-3s at the mitochondrial level. It’s a nuclear receptor that activates when omega-3s bind to it, switching on anti-inflammatory gene expression and improving insulin sensitivity. Think of PPARG as the lock, and omega-3s as the key. Variants in PPARG change how easily that key turns the lock.

Common PPARG variants, particularly Pro12Ala (rs1801282), alter how sensitively cells respond to omega-3 signaling. People with the Ala12 allele, carried by roughly 20-30% of the population, have enhanced insulin sensitivity and may show better metabolic response to omega-3 supplementation. People with Pro/Pro, the more common genotype, show diminished response. The same dose of omega-3 produces stronger anti-inflammatory effects in Ala12 carriers than in Pro/Pro individuals.

If you have Pro/Pro PPARG, you might notice that omega-3 supplementation hasn’t improved your blood sugar stability, inflammation markers, or triglycerides as much as expected. You’re not failing to respond; you’re responding, just less dramatically than other people taking the same dose. This doesn’t mean omega-3s don’t work for you. It means you might need higher doses, or you might benefit from combining omega-3s with other insulin-sensitizing interventions.

APOE codes for apolipoprotein E, a protein that packages cholesterol and omega-3s for transport into the brain. It’s the primary mechanism your brain uses to load EPA and DHA into neural tissue. APOE comes in three flavors: APOE2, APOE3, and APOE4. Your genotype determines how efficiently your brain can absorb and use omega-3s, and how vulnerable your brain is to neurodegeneration.

APOE4, carried by roughly 25% of the European ancestry population, creates a fundamentally different relationship between your brain and omega-3s. APOE4 carriers have lower baseline brain omega-3 levels and higher risk of Alzheimer’s disease. APOE4 individuals show measurably better cognitive and neuroprotective outcomes with consistent high-dose omega-3 supplementation compared to APOE3 or APOE2 carriers. For APOE4 carriers, omega-3s shift from optional to medically important.

If you’re an APOE4 carrier, you might notice brain fog more easily, memory feels less sharp, or you’re more sensitive to cognitive decline as you age. Your omega-3 requirements are genuinely different from someone with APOE3. Standard doses may be insufficient for your brain’s neuroprotective needs. This isn’t weakness. It’s biology. Your brain needs more omega-3 support to maintain the same level of protection.

VDR is the vitamin D receptor, but its job extends far beyond vitamin D metabolism. VDR is expressed on cell membranes and in mitochondria, where it regulates the transport of fatty acids, including omega-3s, into cells and organelles. A broken VDR doesn’t just impair vitamin D function; it impairs the cellular uptake machinery for omega-3s themselves. Your cells cannot absorb what’s circulating in your bloodstream.

VDR variants, particularly FokI (rs2228570), are carried by roughly 30-50% of the population depending on ancestry. The short form (S) of FokI, carried by roughly half of people, produces a shorter, more active VDR protein. The long form (L) produces a longer, less efficient protein. People with the LL genotype show impaired intracellular omega-3 accumulation even when blood omega-3 levels are adequate. Your bloodwork looks fine. Your cells are starving.

You might supplement with omega-3s, see your blood omega-3 index improve, and feel no cognitive, mood, or inflammatory benefit. Your joints might still feel stiff. Your brain might still feel foggy. This is classic VDR dysfunction. Your blood levels improved but your cells never actually received the omega-3s because your cellular transport system is impaired.

MTHFR is not directly an omega-3 gene, but it controls methylation capacity, which determines how efficiently your body can mount anti-inflammatory responses to omega-3 supplementation. When you take omega-3s, your tissues respond by upregulating anti-inflammatory gene expression. This process requires methylation donors (SAM, created from the methylation cycle that MTHFR controls). A broken methylation cycle limits your anti-inflammatory response capacity, even if you’re taking plenty of omega-3s.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces methylenetetrahydrofolate reductase activity by 40-70%. People with C677T have impaired methylation capacity, which dampens the anti-inflammatory effect of omega-3 supplementation. You’re taking the right supplement, but your body cannot fully utilize it because the methylation cycle that amplifies omega-3 responses is broken.

You might take omega-3s, see your blood levels improve, but notice your inflammatory markers (CRP, homocysteine) don’t improve as expected. Your mood might not shift as much as it should. Your joint pain might persist. This is often because MTHFR variants limit the body’s ability to convert the omega-3 signal into full anti-inflammatory gene expression. The omega-3s are there. Your body is not responding as powerfully as it could.